Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL
A phase 2 trial of Belzutifan in pheochromocytoma and paraganglioma, run by Merck Sharp & Dohme LLC, now recruiting.
Overview
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015) is a phase 2 interventional study registered as NCT04924075 by Merck Sharp & Dohme LLC, with 355 participants planned, started 2021-08-12 and due to reach its primary completion in 2029-12-27. Interventions recorded: Belzutifan. Conditions listed: Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor, Von Hippel-Lindau Disease, Advanced Gastrointestinal Stromal Tumor. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)
Shares Belzutifan, Merck & Co. (MSD).
- TrialA Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6
Shares Belzutifan, Merck & Co. (MSD).
- TrialSubstudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (
Shares Belzutifan, Merck & Co. (MSD).
- TrialPembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)
Shares Belzutifan, Merck & Co. (MSD).
- TrialExtension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)
Shares Belzutifan, Merck & Co. (MSD).
- TrialA Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study
Shares Belzutifan, Merck & Co. (MSD).
- TrialStudy of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)
Shares Belzutifan, Merck & Co. (MSD).
- TrialSubstudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)
Shares Belzutifan, Merck & Co. (MSD).